Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Small Molecule CXCR4 Nuclear Medicine Drug
- Development stage
- Preclinical
- Lead developer
- Pentixapharm
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Small Molecule CXCR4 Nuclear Medicine Drug is a radiolabeled small molecule imaging agent developed by the National Atomic Research Institute (NARI). It specifically targets the C-X-C chemokine receptor type 4 (CXCR4), which is highly expressed on activated macrophages within atherosclerotic plaques. By binding to these receptors, the drug enables the non-invasive visualization of inflammatory lesions and vulnerable plaques in cardiovascular disease using nuclear medicine imaging techniques. Intended for intravenous administration, this agent was recognized as one of the top highlight technologies at the 2023 National Innovation Awards in Taiwan. It is currently in preclinical development for the imaging of atherosclerosis.
- Other names
- 小分子CXCR4核醫藥物Small Molecule CXCR4 Radiopharmaceutical
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on Small Molecule CXCR4 Nuclear Medicine Drug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Small Molecule CXCR4 Nuclear Medicine Drug.